Dose-finding designs for HIV studies
From MaRDI portal
Recommendations
- Some statistical issues in the design of HIV-1 vaccine and treatment trials
- Design of viral dynamic studies for efficiently assessing potency of anti-HIV therapies in AIDS clinical trials
- The treatment versus experimentation dilemma in dose finding studies
- scientific article; zbMATH DE number 1984442
- Dose-Finding Based on Efficacy-Toxicity Trade-Offs
Cites work
- Consistency of continual reassessment method under model misspecification
- Continual Reassessment Method: A Likelihood Approach
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- Estimating the Probability of Toxicity at the Recommended Dose Following a Phase I Clinical Trial in Cancer
- scientific article; zbMATH DE number 3746271 (Why is no real title available?)
- Miscellanea. A stopping rule for the continual reassessment method
- Using a one-parameter model to sequentially estimate the root of a regression function.
Cited in
(34)- Flexible link continual reassessment methods for trivariate binary outcome phase I/II trials
- Adaptive clinical trial designs for phase I cancer studies
- Adaptive designs for selecting drug combinations based on efficacy-toxicity response
- Adaptive designs for dose-finding based on efficacy-toxicity response
- Optimizing the concentration and bolus of a drug delivered by continuous infusion
- Sequential methods in multi-arm clinical trials
- Directed walk designs for dose-response problems with competing failure modes
- Dynamic calibration of pharmacokinetic parameters in dose-finding studies
- Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios
- Patient‐Specific Dose Finding Based on Bivariate Outcomes and Covariates
- Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials
- On generalized multinomial models and joint percentile estimation
- Patient-specific dose finding in seamless phase I/II clinical trials
- Biometric practicesimple benchmark for complex dose finding studies
- Implementation of a Bayesian Design in a Dose‐Escalation Study of an Experimental Agent in Healthy Volunteers
- Up-and-Down Designs for Selecting the Dose with Maximum Success Probability
- A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes
- Bayesian phase I/II adaptively randomized oncology trials with combined drugs
- A Bayesian design for phase I cancer therapeutic vaccine trials
- Early phase dose-finding trials in virology
- Surv-CRM-12: a Bayesian phase I/II survival CRM for right-censored toxicity endpoints with competing disease progression
- Stopping rules for phase II clinical trials: an overview
- A Bayesian dose-finding design for phase I/II clinical trials with nonignorable dropouts
- A new approach to designing phase I-II cancer trials for cytotoxic chemotherapies
- Phase I/II adaptive design for drug combination oncology trials
- Dimension of model parameter space and operating characteristics in adaptive dose-finding studies
- Two-stage dose finding for cytostatic agents in phase I oncology trials
- Developing a Bayesian adaptive design for a phase I clinical trial: a case study for a novel HIV treatment
- Sequential monitoring of phase I dose expansion cohorts
- A robust two-stage design identifying the optimal biological dose for phase I/II clinical trials
- Dose-Finding Based on Efficacy-Toxicity Trade-Offs
- Defining utility as a measure of preference under uncertainty in phase I-II oncology dose finding trials
- Continual reassessment and related dose-finding designs
- Bayesian models and decision algorithms for complex early phase clinical trials
This page was built for publication: Dose-finding designs for HIV studies
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q3078854)
